Expedited Access to Biosimilars Act
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Expedited Access to Biosimilars Act (S.1414) is a Senate bill introduced in the 119th Congress aimed at facilitating faster access to biosimilar drugs. Biosimilars are medical products highly similar to already approved biologic drugs, potentially offering more affordable treatment options. The bill is currently in process and has been placed on the Senate Legislative Calendar under General Orders, indicating it is awaiting further consideration. However, no official summary or full text is publicly available at this time, limiting detailed analysis of its provisions.
S.1414 seeks to accelerate the availability of biosimilar drugs, but detailed provisions and impacts remain unclear due to the absence of a full bill text and official summary.
- The bill is focused on the health policy area, specifically related to biosimilar drugs.
- It has been placed on the Senate Legislative Calendar, indicating it is pending further legislative action.
- No official summary or full text is currently available, restricting detailed understanding of its mechanisms or requirements.
['Patients who may gain faster access to biosimilar medications', 'Healthcare providers prescribing biosimilars', 'Pharmaceutical companies involved in biosimilar development and marketing', 'Potentially health insurance providers and payers through cost savings']
['Lack of publicly available full text and summary limits transparency and understanding of implementation details', 'Unclear how expedited access will be managed or regulated, raising questions about oversight and safety standards', 'Potential cost implications for regulatory agencies or healthcare systems are not specified', 'No information on enforcement mechanisms or authority changes']
The bill is part of ongoing legislative efforts to address healthcare costs and access by promoting biosimilar drugs as alternatives to biologics. It reflects a policy interest in improving drug affordability and availability. Placement on the Senate Legislative Calendar suggests it has some level of support or priority but has not yet advanced to a vote or further committee action.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased competition in the biologics market could influence pricing and innovation dynamics.', 'Faster access to biosimilars may lead to changes in prescribing practices among healthcare providers.', 'Healthcare payers might experience cost savings if biosimilars become more widely available.']
The absence of a full bill text and official summary limits the ability to fully assess the bill’s provisions, enforcement mechanisms, and fiscal impacts. Transparency about the bill’s specific regulatory changes and implementation strategies is essential for informed public and legislative scrutiny.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.